Saumitra Ray

ORCID: 0000-0003-0204-0199
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Blood Pressure and Hypertension Studies
  • Heart Failure Treatment and Management
  • Lipoproteins and Cardiovascular Health
  • Acute Myocardial Infarction Research
  • Heart Rate Variability and Autonomic Control
  • Sepsis Diagnosis and Treatment
  • Diabetes, Cardiovascular Risks, and Lipoproteins
  • Coronary Interventions and Diagnostics
  • Cardiac Imaging and Diagnostics
  • Sodium Intake and Health
  • Health Systems, Economic Evaluations, Quality of Life
  • Cardiac pacing and defibrillation studies
  • Diabetes Treatment and Management
  • Cardiac Health and Mental Health
  • Cardiovascular Function and Risk Factors
  • Antiplatelet Therapy and Cardiovascular Diseases
  • Pharmaceutical Economics and Policy
  • Hemodynamic Monitoring and Therapy
  • COVID-19 Clinical Research Studies
  • Cardiac, Anesthesia and Surgical Outcomes
  • Hormonal Regulation and Hypertension
  • Cardiovascular Health and Disease Prevention
  • Renin-Angiotensin System Studies
  • Cardiovascular Health and Risk Factors
  • Cardiac Valve Diseases and Treatments

Guy's and St Thomas' NHS Foundation Trust
2025

Vivekananda Institute of Medical Sciences
2010-2024

AMRI Hospitals
2011-2024

Liwa College
2024

Fortis Hospital
2023

Fortis Healthcare
2010-2023

Apollo Hospitals
2023

Max Super Speciality Hospital
2023

Bombay Hospital
2023

Creative Commons
2023

Objective : In 2016, the Lipid Association of India (LAI) developed a cardiovascular risk assessment algorithm and defined low-density lipoprotein cholesterol (LDL-C) goals for prevention atherosclerotic disease (ASCVD) in Indians. The recent refinements role various factors subclinical atherosclerosis prediction ASCVD necessitated updating treatment goals. Methods LAI core committee held twenty-one meetings webinars from June 2022 to July 2023 with experts across critically reviewed latest...

10.1016/j.jacl.2024.01.006 article EN cc-by-nc-nd Journal of clinical lipidology 2024-02-08

The benefits of improved clinical outcomes through blood pressure (BP) reduction have been proven in multiple trials and meta-analyses. new (2023) guideline from the European Society Hypertension (ESH) includes β-blockers within five main classes antihypertensive agents suitable for initiation pharmacotherapy combination with other agents. This is contrast to 2018 edition ESH guidelines that recommended use primarily patients compelling indications such as cardiovascular comorbidities, e.g....

10.1080/03007995.2024.2318003 article EN cc-by-nc-nd Current Medical Research and Opinion 2024-04-01

Dyslipidemias are the most important coronary artery disease (CAD) risk factor. Proper management of dyslipidemia is crucial to control epidemic premature CAD in India. Cardiological Society India strived develop consensus-based guidelines for better lipid prevention and treatment. The executive summary provides a bird's eye-view 'CSI: Clinical Practice Guidelines Dyslipidemia Management' published this issue Indian Heart Journal. focused on busy clinician encourages evidence-based patients...

10.1016/j.ihj.2023.11.271 article EN cc-by-nc-nd Indian Heart Journal 2023-12-04

Blood cholesterol has firmly been established as a crucial risk factor for the development of atherosclerotic cardiovascular disease (ASCVD) by elegant epidemiological studies. Naturally, means to reduce blood level took centerstage research in this field. After initial lukewarm results with nicotinic acid, fibrates and some other agents, statins emerged most effective class medicine cholesterol; particular, atherogenic low density lipoprotein (LDL-C). Also, they are very safe well...

10.1016/j.ihj.2023.11.267 article EN cc-by-nc-nd Indian Heart Journal 2024-03-01

Abstract Background Upadacitinib (UPA), a janus kinase inhibitor (JAKi) with selectivity for JAK-1, is licensed in ulcerative colitis (UC) and Crohn’s disease (CD). Acne was seen commonly the CD UC registration studies of UPA. We sought to investigate prevalence acne real-world cohort IBD patients using Methods performed retrospective review all who received UPA UC, or IBD-unclassified (IBD-U) between Sep 2022 2024 at large tertiary referral centre. Data were collated from electronic health...

10.1093/ecco-jcc/jjae190.1333 article EN Journal of Crohn s and Colitis 2025-01-01

To examine the impact of implementing sepsis bundle in multiple Asian countries, having 'team' vs. 'non-team' models patient care. Prospective cohort study. Eight urban hospitals, five countries Asia. Adult patients with severe or septic shock. Implementation was divided into six quartiles: Baseline, Education and four Quality Improvement quartiles. Quarterly compliance in-hospital mortality respect to completion implementation model. In team model, championed by intensivists, where...

10.1093/intqhc/mzs045 article EN International Journal for Quality in Health Care 2012-08-16

Unhealthy eating and lack of exercise during adolescence culminated into earlier onset increasing burden atherosclerotic cardiovascular diseases (CVDs) worldwide. Among urban Indian adolescents, prevalence these risk factors CVD seemed to be high, but data regarding their pattern predictors was limited. To address this dearth information, a survey conducted among adolescent school-students in Kolkata, highly populated metro city eastern India. During January–June, 2014, 1755 students...

10.1186/s12889-017-4390-9 article EN cc-by BMC Public Health 2017-05-18

A case control study was designed to assess whether the prevalence of ACE gene polymorphism has any role in development CAD. The included unrelated 217 cases with CAD and 255 healthy controls. PCR done using primers followed by agarose gel electrophoresis for different polymorphisms. Multiple logistic regression analysis carried out find association between studied genotypes lifestyle as well biochemical risk factors. Both DD [OR: 2.16; 95%CI: (60.60–67.40)] ID 1.48; (93.28–97.72)] showed...

10.1016/j.ihj.2012.08.005 article EN cc-by-nc-nd Indian Heart Journal 2012-08-27

Vildagliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor is effective in reducing HbA1c levels patients with type 2 diabetes (T2DM) when administered as monotherapy, dual or triple combination therapy. In India, Vildagliptin commonly prescribed T2DM because it reduces mean amplitude of glycemic excursion (MAGE), has lower risk hypoglycemia and weight neutral. Early therapy vildagliptin metformin well-tolerated T2DM, regardless age ethnicity. view already existing data on the latest emerging...

10.1177/11795514231203911 article EN cc-by-nc Clinical Medicine Insights Endocrinology and Diabetes 2024-01-01

Studies on the changes in presentation and management of acute myocardial infarction (AMI) during COVID-19 pandemic from low- middle-income countries are limited. We sought to determine number admissions, practices, outcomes AMI period India.

10.1016/j.ihj.2021.06.003 article EN cc-by-nc-nd Indian Heart Journal 2021-06-18

Contrast-induced nephropathy (CIN) is a fairly common yet under-recognized clinical condition in the interventional cardiological practice. A 25% or more than 0.5 mg/dl rise of serum creatinine generally accepted as defining CIN. The most important risk factors for CIN are pre-existing renal disease, volume contrast media, nature and diabetes mellitus. Among various postulated pathophysiological mechanisms precipitation CIN, intra-renal vasoconstriction, oxidative tubular injury best...

10.15761/jic.1000109 article EN cc-by Journal of Integrative Cardiology 2015-01-01

Background: Gene-environment interaction is an important aspect in the development of coronary artery disease (CAD).The mutation (677C-T) methylenetetrahydrofolate reductase (MTHFR) gene results a decrease enzyme activity that leads to mild hyperhomocysteinemia. Elevated plasma level homocysteine has been recognized as independent risk factor for cardiovascular disease.A case-control study was designed assess whether prevalence some MTHFR polymorphisms have any role CAD. Materials and...

10.4103/0975-3583.70922 article EN Journal of Cardiovascular Disease Research 2010-07-01

The effectiveness of amlodipine has been reported in clinical trials India. However, real-world data on the India is limited.To provide evidence regarding as monotherapy or combination with other antihypertensive drugs (AHDs) Indian patients essential hypertension.Electronic medical record adult who were diagnosed hypertension (≥ 140/90 mmHg) and prescribed add-on therapy retrospectively analyzed. Patients classified based number AHD classes initiation amlodipine. Change systolic (SBP)...

10.1007/s40801-020-00211-w article EN cc-by-nc Drugs - Real World Outcomes 2020-09-08
Coming Soon ...